Free Trial

Ipsen (OTCMKTS:IPSEY) Share Price Passes Above 200-Day Moving Average - Time to Sell?

Ipsen logo with Medical background

Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $29.15 and traded as high as $29.93. Ipsen shares last traded at $29.30, with a volume of 624 shares traded.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Ipsen in a report on Wednesday, April 2nd.

View Our Latest Report on IPSEY

Ipsen Stock Up 1.0%

The business has a fifty day moving average of $28.37 and a two-hundred day moving average of $29.14.

Ipsen Company Profile

(Get Free Report)

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Featured Stories

Should You Invest $1,000 in Ipsen Right Now?

Before you consider Ipsen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ipsen wasn't on the list.

While Ipsen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Unique Robotaxi Play Could Deliver 10X Returns
NVIDIA’s Secret Picks? 3 Stocks Rising With the AI Giant
NVIDIA Earnings Preview: HUGE Stock Move Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines